Lexaria Bioscience Corp Stock Price, News & Analysis

Lexaria Bioscience Corp. has selected InClin, a California-based CRO, to manage its upcoming Phase 1b hypertension study, titled HYPER-H23-1, evaluating the safety and efficacy of its patented DehydraTECH-CBD. The study aims to assess the treatment on 120 patients with Stage 1 and Stage 2 hypertension, following successful FDA pre-IND meeting outcomes. Lexaria plans to file its IND application this summer, anticipating FDA authorization within 60 days. Previous studies indicated that DehydraTECH-CBD significantly reduced blood pressure with no serious adverse events, setting it apart from other CBD formulations. The company is also working on the necessary stability testing for its drug product, which is crucial for the IND submission.

Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) has announced the receipt of four new patents, enhancing its intellectual property portfolio globally. In Japan, a patent for Stable Ready-to-Drink Beverage Compositions marks the 5th awarded in the country; in Australia, a patent for Enhanced Delivery of Antiviral Agents becomes the 10th. Canada has allowed a patent for Nicotine Compounds, and the USA has granted a patent for Treating Hypertension, crucial for future FDA applications. These patents underscore Lexaria's commitment to expanding its DehydraTECH technology, vital in the lucrative cardiovascular drugs market projected to grow from US$146.5 billion in 2022 to $173.5 billion by 2026. With these additions, Lexaria's patent portfolio increases to 32 granted patents worldwide.

Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) has completed its diabetes study DIAB-A22-1, demonstrating significant positive effects of DehydraTECH-CBD on obese diabetic rats. Key outcomes include:

• Approximately 7% weight loss over 8 weeks, with treated animals losing weight while untreated animals gained weight.
• Improved metabolic function indicated by stable food and water intake despite weight loss.
• Significant reductions in triglyceride levels, with the lower dose achieving over 25% reduction compared to untreated rats.
• Potential enhancement of activity levels at lower doses of DehydraTECH-CBD.

These findings encourage further investigation into using DehydraTECH-CBD for diabetes treatment.

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) has announced significant results from its clinical study HYPER-H21-4, which assessed the blood pressure-lowering effects of its DehydraTECH-processed CBD capsules. The study demonstrated a substantial and sustained reduction in blood pressure over five weeks, with no serious adverse events reported. Key findings include a 28.5% decrease in serum catestatin levels and a statistically significant drop in mean arterial pressure. These results suggest that Lexaria's CBD formulation may offer a novel therapeutic approach for managing hypertension, particularly for patients resistant to standard treatments.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has appointed Julian Gangolli, the former President of GW Pharmaceuticals USA, as a Strategic Advisor. Gangolli, known for overseeing the FDA approval of Epidiolex, aims to assist Lexaria in commercializing its DehydraTECH technology. The company is focusing on executing its technology portfolio in 2023. Gangolli's background includes leadership roles at Allergan, further strengthening Lexaria's team. He will receive stock options for 5,000 shares at an exercise price of $2.73. Lexaria's DehydraTECH enhances drug absorption and has 28 patents granted worldwide.